Celularity Faces Nasdaq Delisting Risk Over Delayed Financial Filings
Celularity Inc., a regenerative and cellular medicine company, disclosed on August 25, 2026 that it received a formal compliance notification from Nasdaq three days earlier regarding overdue financial reporting requirements.
The notification, dated August 21, 2026, came from Nasdaq's Listing Qualifications Department and cited violations of Nasdaq Listing Rule 5250(c)(1), which mandates that publicly traded companies file all required periodic financial reports with the U.S. Securities and Exchange Commission in a timely manner.
The Florham Park, New Jersey-based company has failed to submit its Quarterly Report on Form 10-Q for the period ended June 30, 2026, and remains delinquent on its Form 10-Q for the period ended March 31, 2026.
Compliance Timeline and Requirements
Nasdaq has given Celularity until September 4, 2026 to submit a plan outlining how it intends to regain compliance with listing requirements. Should the exchange grant an exception, the company would have until November 16, 2026 to file the delinquent reports—a maximum extension of 180 calendar days from the original due date of the first missing filing.
The notification does not immediately affect the trading status of Celularity's common stock, which continues to be listed and traded on the Nasdaq Capital Market under the ticker symbol "CELU."
Company Response
In its statement, Celularity indicated it is working to complete and file both outstanding quarterly reports as quickly as possible. The company did not provide specific reasons for the filing delays or an estimated completion date.
About Celularity
Celularity describes itself as a longevity-focused regenerative and cellular medicine company that develops and manufactures placental-derived cellular therapies. The company trades publicly on the Nasdaq Capital Market.
The forward-looking statements in the company's announcement acknowledged that actual results may differ materially from current expectations due to various risks and uncertainties detailed in its regulatory filings with the Securities and Exchange Commission.
